There is evidence from retrospective studies that radical cystectomy with extended pelvic lymph node dissection provides better staging and outcomes than limited lymph node dissection. However, the optimal limits of extended lymph node dissection remain unclear. We compared oncological outcomes at 2 cystectomy centers where 2 different extended lymph node dissection templates are practiced to determine whether removing lymphatic tissue up to the inferior mesenteric artery confers an additional survival advantage. Patients undergoing radical cystectomy and extended lymph node dissection with curative intent from 1985 to 2005 were included in analysis if they met certain criteria, including clinically organ confined urothelial bladder carcinoma (cN0M0), pathological stage pT2-pT3, negative surgical margins and no neoadjuvant therapy. Survival and recurrence data were analyzed. Demographic data and pathological subgroup distribution (pT2 and pT3) were similar in the 554 University of Southern California and 405 University of Bern patients. University of Southern California patients had higher median number of lymph nodes removed than University of Bern patients (38 vs 22, p <0.0001) and a higher incidence of lymph node metastasis (35% vs 28%, p = 0.02). However, the University of Southern California and University of Bern groups had similar 5-year recurrence-free survival for pT2pN0-2 (57% vs 67%) and pT3pN0-2 (32% vs 34%) disease (p = 0.55 and 0.44, respectively). The overall recurrence rate was equal at the 2 institutions (38%). Meticulous extended lymph node dissection up to the mid-upper third of the common iliac vessels appears to provide survival and recurrence outcomes similar to those of a super extended template up to the inferior mesenteric artery. Complete skeletonization in the extended lymph node dissection template is more important than nodal yield. This does not exclude the possibility that certain patient subgroups with suspicious nodes or after neoadjuvant chemotherapy may benefit from more extensive lymph node dissection.
Objective: To evaluate oncological outcome trends over the last three decades in patients after radical cystectomy ( RC ) and extended pelvic lymph node ( LN ) dissection. Patients and Methods: Retrospective analysis of the U niversity of S outhern C alifornia ( USC ) RC cohort of patients (1488 patients) operated with intent to cure from 1980 to 2005 for biopsy confirmed muscle‐invasive urothelial bladder cancer. To focus on outcomes of unexpected ( cN0M0 ) LN ‐positive patients, the USC subset was extended with unexpected LN ‐positive patients from the U niversity of B erne ( UB ) (combined subgroup 521 patients). Patients were grouped and compared according to decade of surgery (1980–1989/1990–1999/≥2000). Survival probabilities were calculated with K aplan– M eier plots, log‐rank tests compared outcomes according to decade of surgery, followed by multivariable verification. Results: The 10‐year recurrence‐free survival was 78–80% in patients with organ‐confined, LN ‐negative disease, 53–60% in patients with extravesical, yet LN ‐negative disease and ≈30% in LN ‐positive patients. Although the number of patients receiving systemic chemotherapy increased, no survival improvement was noted in either the entire USC cohort, or in the combined LN ‐positive USC‐UB cohort. In contrast, patient age at surgery increased progressively, suggesting a relative survival benefit. Conclusions: Radical surgery remains the mainstay of therapy for muscle‐invasive bladder cancer. Yet, our study reveals predictable outcomes but no survival improvement in patients undergoing RC over the last three decades. Any future survival improvements are likely to result from more effective systemic treatments and/or earlier detection of the disease.
Objective: To analyse the long‐term outcomes of patients with lymph node ( LN )‐positive bladder cancer, who did not receive any adjuvant therapy after radical cystectomy ( RC ) and extended pelvic lymph node dissection ( ePLND ). Patients and Methods: We conducted a retrospective, combined cohort analysis based on two prospectively maintained cystectomy databases from the U niversity of S outhern C alifornia and the U niversity of B ern. Eligible patients underwent RC with ePLND for cN0M0 disease but were found to have LN ‐positive disease. No patient had neoadjuvant therapy, and all had negative surgical margins. Kaplan– M eier plots were used to estimate recurrence‐free survival ( RFS ) and overall survival ( OS ). Subgroup comparisons were performed using log‐rank tests, and multivariable analysis was based on C ox proportional hazard models. Results: Of 521 patients with LN ‐positive disease, 251 (48%) never received adjuvant therapy. Although the pathological stage distribution was similar, the 251 patients who did not receive adjuvant therapy were older and had both fewer total and positive LNs than those who underwent adjuvant therapy. The median RFS for patients treated with RC alone was 1.6 years. Recurrences mainly occurred <2 years after RC , resulting in 5‐ and 10‐year RFS rates of 32 and 26%, respectively. Pathological T stage, the total number of LNs and the number of positive LNs detected were independent predictors of RFS and OS . Conclusions: In this study, 25% of patients with documented LN metastases who did not receive adjuvant therapy were cured with RC and ePLND ; however, a few relapses may occur later than 3 years. Predictors of survival were pathological T stage, the number of total LNs and the number of positive LNs identified.